Nebulabio provide cutting-edge, customized Serum-Free Expression System development and implementation services to empower the production of recombinant proteins, antibodies, and viral vectors. The elimination of animal-derived serum (e.g., Fetal Bovine Serum, FBS) from cell culture processes is a critical advancement in biomanufacturing, addressing major concerns regarding supply chain volatility, compositional variability, and regulatory risks associated with adventitious agents. Our expertise lies in designing, optimizing, and transitioning client-specific cell lines—particularly CHO and HEK293—into robust, high-performing serum-free and, where required, chemically defined (CD) platforms. We enable our partners to achieve superior product consistency, enhance process scalability, simplify downstream purification, and ensure compliance with stringent regulatory guidelines for therapeutic and diagnostic product development. From medium formulation screening to complete process development, we offer an end-to-end solution to future-proof your bioproduction pipeline.
☞Design of Serum-Free Expression Systems
The design of an effective serum-free system is a multifaceted engineering challenge, moving beyond mere serum elimination to create a balanced environment that supports high cell viability, productivity, and product quality. Our design philosophy is built on several core principles:
Figure1.Generalized workflow for cell-free pathway prototyping.
①Basal Medium Foundation: We start with a high-quality, chemically defined basal medium containing essential inorganic salts, amino acids, vitamins, and energy sources (e.g., glucose, glutamine). The exact formulation is selected or customized based on the host cell type and metabolic profile.
②Critical Supplementation: Serum provides hundreds of bioactive components. We systematically replace these functions with defined supplements:
● Growth & Survival Factors: Recombinant insulin or insulin-like growth factors (IGF), lipids (cholesterol, fatty acids), and trace elements (selenium, iron, copper).
● Carrier & Detoxifying Agents: Chemically defined proteins (e.g., recombinant albumin) or polymers (e.g., Pluronic F-68) to replace bovine serum albumin (BSA) for lipid transport, shear protection, and detoxification.
● Hormones & Attachment Factors: For adherent cell adaptation to suspension culture, we incorporate defined substitutes for attachment factors.
③Metabolic Optimization: We analyze and tune the medium to prevent the accumulation of metabolic waste products (e.g., ammonia, lactate) that can inhibit growth and productivity, often through fed-batch strategy design.
④Cell Line-Specific Adaptation: There is no universal "best" formula. Our process involves the gradual, controlled adaptation of your specific progenitor cell line (e.g., from serum-containing to serum-free, then to suspension culture) to minimize adaptation stress and select for a stable, high-producing population.
| ☎ +86-15801534258 | ✉ info@nebulabio.cn | Contact Us ☜☜ |
☞Classification of Serum-Free Expression Systems
Serum-free systems can be categorized based on their level of definition and composition:
● Serum-Free Media (SFM): Contains no components of animal origin, but may include hydrolysates (plant-derived or from non-animal sources) or partially purified fractions. While more defined than serum-containing media, it is not fully chemically defined. It offers a significant step forward in reducing risk and variability.
● Chemically Defined Media (CDM): Represents the gold standard. All components are known chemical entities of pure grade. There are no proteins, hydrolysates, or components of unknown composition. CDM offers the highest level of lot-to-lust consistency, simplifies regulatory filing (no TSE/BSE risk), and provides unparalleled process control.
● Protein-Free Media (PFM):A subset of SFM that contains no proteins of any origin (e.g., no albumin, insulin, transferrin). Proteins are replaced with synthetic polymers, defined lipids, and other non-proteinaceous compounds. PFM significantly simplifies downstream purification.
● Animal-Component Free (ACF) Media: Guarantees the complete absence of any raw material derived from animals throughout the supply chain, which is critical for certain regulatory pathways and ethical considerations. It can be SFM or CDM.
Our service platform supports the development and deployment of all these categories, guiding you to the optimal choice for your product stage (research, clinical, commercial) and regulatory strategy.
☞Nebulabio Service Content and Process
Our comprehensive service guides you through the complete journey of establishing a high-performance serum-free expression process.
Service Content: ● Cell Line Adaptation Services: We adapt your existing research or master cell bank from serum-dependent adherent culture to serum-free suspension culture in our proprietary or client-preferred media platforms. ● Custom Medium Optimization & Formulation: Screening of commercial SFM/CDM libraries and/or targeted optimization of key medium components (feeds, supplements) to maximize your cell line's specific growth, titer, and product quality (e.g., glycan profile). ● Complete Process Development: Integration of the optimized serum-free medium with a fed-batch or perfusion process in shake flasks and bioreactors. We establish baseline process parameters and define critical quality attributes (CQAs). ● Analytical Support & Comparability Studies: We perform head-to-head comparisons between your legacy serum-containing process and the new serum-free process, demonstrating equivalence or superiority in product quality, purity, and biological activity. |
Nebulabio Service Process:
Process Description: ● Audit & Analysis: We assess your current cell line status, growth characteristics, and production process. ● Strategy Design: We jointly decide on the target platform (e.g., CDM) and select candidate basal media. ● Adaptation & Screening: Your cells undergo a controlled, multi-passage adaptation protocol. Adapted pools are single-cell cloned if necessary to isolate top-performing clones in the new system. ● Optimization: Using Design of Experiments (DoE), we optimize feed strategies and key supplements to boost titer and quality. ● Scale-up Confirmation: The optimized process is transferred to benchtop bioreactors to confirm performance under controlled conditions. ● Delivery: We deliver the adapted and characterized research cell bank (RCB), the finalized medium/feed formulations, a detailed process protocol, and a comprehensive analytical comparability report. |
☞Applications of Serum-Free Expression Systems
The implementation of serum-free systems is essential across the biopharmaceutical industry:
● Therapeutic Protein & Monoclonal Antibody Production: The standard for all clinical and commercial manufacturing of mAbs, Fc-fusion proteins, and enzymes (e.g., CHO-based processes). Ensures patient safety, regulatory compliance, and supply chain robustness.
● Vaccine Production: Critical for the production of viral vaccines (using cell substrates like Vero, MDCK, HEK293) and recombinant vaccine antigens, eliminating the risk of introducing animal viruses or prions into the product.
● Viral Vector Manufacturing for Cell & Gene Therapy: Essential for producing clinical-grade AAV, lentivirus, and adenovirus vectors in HEK293 or insect cell platforms, where serum can interfere with transduction efficiency and poses a significant safety risk.
● Industrial Enzyme & Specialty Protein Production: Enables scalable, cost-effective, and consistent microbial (e.g., yeast in defined media) and mammalian production of non-therapeutic proteins.
● Cell Therapy (Advanced): While the cells themselves are the product, serum-free media are increasingly used in the ex vivo expansion and differentiation of stem cells and immune cells (e.g., CAR-T) to enhance process control and safety.
☞Why Choose Nebulabio?
| Proven Expertise in Complex Adaptation | Platform-Based yet Fully Customized Approach | |
| We have a unparalleled track record of successfully adapting difficult-to-transition cell lines, including older research lines and sensitive primary cells, into high-titer serum-free suspension cultures. | We leverage deep knowledge from our platform media and processes, but treat each project as a unique challenge, tailoring every step to your cell line and product. | |
| Focus on Product Quality Attributes (PQAs) | Seamless Scalability | |
| Our optimization work goes beyond just cell growth and titer. We design experiments to actively monitor and control critical PQAs like glycosylation, charge variants, and aggregation from the outset. | Our development work is conducted with scalability in mind from day one. Processes developed in shake flasks are designed to translate predictably to stirred-tank bioreactors. | |
| Regulatory-Driven Mindset | Dedicated Partnership | |
| Our scientists understand the regulatory requirements for biologicals. We develop processes and generate documentation (comparability reports, SOPs) that support IND/IMPD and BLA/MAA filings. | You are assigned a dedicated project team that provides transparent communication, regular data reviews, and strategic guidance throughout the entire transition project. |
☞Transition with Confidence to a Defined Future
Partner with Nebulabio to eliminate the risks and limitations of serum-dependent culture. Our Serum-Free Expression System service provides the scientific rigor, proven methodology, and dedicated partnership needed to successfully modernize your production platform, enhancing both product quality and regulatory readiness.
Contact us to schedule a consultation and discuss transitioning your cell line to a serum-free future.
For more information, please contact us at info@nebulabio.cn or +86-15801534258.
